BMS, Novartis restructuring

February 2008
Pharmaceutical Representative;Feb2008, Vol. 38 Issue 2, p8
The article reports on the restructuring of two pharmaceutical company Bristol-Myers Squibb Co. and Novartis AG. Bristol-Myers Squibb Co. announced a strategic initiative that focuses on the company's efforts and cutting $1.5 billion in pre-tax costs by 2010. On the other hand, Novartis AG is planning to reduce its operations, remove organizational layers, eliminate 2,500 full-time positions worldwide that could result in pre-tax savings of $1.6 billion in 2010.


Related Articles

  • livinglifebetter.com and healthandage.com case studies.  // Livinglifebetter.com & Healthandage.com Case Studies: Reaching a;Mar2004, p1 

    Presents information about two lifestyle web sites, Bristol-Myers Squibb Co.'s livingbetter.com and Novartis AG's healthandage.com. Advantages gained by pharmaceutical companies by employing a lifestyle web site; Description of the web site livinglifebetter.com; Diseases covered by...

  • World News & Analysis. Gopal, Kevin // Pharmaceutical Executive;Nov2000, Vol. 20 Issue 11, p34 

    Presents updates on the pharmaceutical industry as of November 2000. Plan of Akzo Nobel to spin-off Organon, its pharmaceutical division; Information on the plans of Bristol-Myers Squibb to sell its Clairol beauty care business and its orthopedic unit, Zimmer, to focus more on medicines;...

  • Investors rush to generic stocks in a pivotal year.  // Drug Store News;8/28/2000, Vol. 22 Issue 12, p46 

    Provides information on the leading generic manufacturers in the United States. Novartis; Barr Labs; Bristol-Myers Squibb; Watson; Boehringer Ingelheim.

  • BIG PHARMA'S FRENETIC WEEK.  // njbiz;7/29/2002, Vol. 15 Issue 31, p3 

    Presents updates on the pharmaceutical industry, as of July 29, 2002. Criticism against the hormone replacement franchise of Wyeth; Drug approval for Zelnorm by Novartis AG; Earnings of Bristol-Myers Squibb.

  • CORPORATE.  // MondayMorning;3/10/2014, Vol. 22 Issue 9, p2 

    The article presents news briefs related to pharmaceutical companies. Bristol-Myers Squibb Co.'s experimental HIV drug controlled the virus in a study that suggests the medicine may help difficult-to-treat patients. Thoratec Corp. issued an safety advisory about the use of the pocket controller...

  • Novartis, BMS Withdraw IBS Drug from European Review.  // Chemical Market Reporter;6/11/2001, Vol. 259 Issue 24, p8 

    Reports on the decision of Novartis and Bristol-Myers Squibb Co. to withdraw their marketing application for the drug Zelmac from the European Agency for the Evaluation of Medicinal Products. Reason for the withdrawal; Forecast on the sales of Zelmac by 2005; Agreement between Novartis and...

  • BMS' OTC pain meds are Novartis' gain. Arnold, Matthew // Medical Marketing & Media;Aug2005, Vol. 40 Issue 8, p8 

    Reports on Novartis' acquisition of the U.S. and Canadian over-the-counter (OTC) business of Bristol-Myers Squibb. Total value of the deal; Novartis' entry into the U.S. market for adult table headache remedies; Terms under the acquisition deal.

  • Pharma should help pay for cancer Rx. M. A. // Medical Marketing & Media;Mar2010, Vol. 45 Issue 3, p11 

    The article reports on the move of the government regulators to urge Novartis AG and Bristol-Myers Squibb Co. to help pay for their leukemia drugs in Great Britain.

  • BMS cuts 500 reps in specialty switch.  // Medical Marketing & Media;Nov2004, Vol. 39 Issue 11, p11 

    This article reports that Bristol-Myers Squibb Co. laid off 500 sales representatives and realigned its reduced primary care field force to focus on its cardiology and diabetes products, part of a move to channel the bulk of its efforts into specialty markets. The move comes amid a series of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics